FWY003 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy Secondary to Age-related Macular Degeneration
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Trial Timeline
Mar 9, 2026 → Aug 22, 2029
NCT ID
NCT07441642About FWY003 + Placebo
FWY003 + Placebo is a phase 2 stage product being developed by Novartis for Geographic Atrophy Secondary to Age-related Macular Degeneration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441642. Target conditions include Geographic Atrophy Secondary to Age-related Macular Degeneration.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441642 | Phase 2 | Recruiting |
Competing Products
20 competing products in Geographic Atrophy Secondary to Age-related Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 77 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |